

World Journal of *Gastroenterology*

World J Gastroenterol 2019 February 7; 25(5): 521-643



**REVIEW**

- 521** Iron and liver fibrosis: Mechanistic and clinical aspects
Mehta KJ, Farnaud SJ, Sharp PA

MINIREVIEWS

- 539** Contribution of ghrelin to functional gastrointestinal disorders' pathogenesis
Koutouratsas T, Kalli T, Karamanolis G, Gazouli M
- 552** Functional gastrointestinal disorders and gut-brain axis: What does the future hold?
Mukhtar K, Nawaz H, Abid S

ORIGINAL ARTICLE**Basic Study**

- 567** Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: *In vitro* inhibition of carcinogenesis
Serhal R, Saliba N, Hilal G, Moussa M, Hassan GS, El Atat O, Alaaeddine N
- 584** Claudin-7 gene knockout causes destruction of intestinal structure and animal death in mice
Xu C, Wang K, Ding YH, Li WJ, Ding L

Retrospective Cohort Study

- 600** Zinc deficiency in patients with chronic pancreatitis
Vujasinovic M, Hedström A, Maisonneuve P, Valente R, von Horn H, Löhr JM, Haas SL

Retrospective Study

- 608** Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years
Kim DK, Kim BR, Jeong JS, Baek YH
- 622** Hepatocellular carcinoma: Can LI-RADS v2017 with gadoteric-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T, Huang ZX, Wei Y, Jiang HY, Chen J, Liu XJ, Cao LK, Duan T, He XP, Xia CC, Song B

SYSTEMATIC REVIEWS

- 632** Fatigue in children and adolescents with inflammatory bowel disease
Van de Vijver E, Van Gils A, Beckers L, Van Driessche Y, Moes ND, van Rheeën PF

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Amedeo Amedei, BSc, Professor, Department of Experimental and Clinical Medicine, University of Florence, Firenze 50134, Italy

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. The *WJG* Editorial Board consists of 642 experts in gastroenterology and hepatology from 59 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, etc. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2018 edition of Journal Citation Report® cites the 2017 impact factor for *WJG* as 3.300 (5-year impact factor: 3.387), ranking *WJG* as 35th among 80 journals in gastroenterology and hepatology (quartile in category Q2).

RESPONSIBLE EDITORS
FOR THIS ISSUE

Responsible Electronic Editor: Yan Huang

Proofing Editorial Office Director: Ze-Mao Gong

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Subrata Ghosh, Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE

Ze-Mao Gong, Director

PUBLICATION DATE

February 7, 2019

COPYRIGHT

© 2019 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Basic Study

Claudin-7 gene knockout causes destruction of intestinal structure and animal death in mice

Chang Xu, Kun Wang, Yu-Han Ding, Wen-Jing Li, Lei Ding

ORCID number: Chang Xu (0000-0003-1634-0870); Kun Wang (0000-0001-5342-5967); Yu-Han Ding (0000-0001-9263-7364); Wen-Jing Li (0000-0002-7814-7390); Lei Ding (0000-0001-7350-8508).

Author contributions: Ding L designed the study; Xu C performed the research and wrote the paper; Wang K and Ding YH fed the mice; Li WJ analysed the data.

Supported by the National Natural Science Foundation of China, No. 81372585 and No. 81772557; and Beijing Health System High Level Training Plan of Health Technical Personnel, No. 2014-3-048.

Institutional review board

statement: The study was reviewed and approved by the Medical Ethics Committee of the Capital Medical University Affiliated Beijing Shijitan Hospital Institutional Review Board.

Institutional animal care and use

committee statement: All protocols were carried out in accordance with relevant guidelines and regulations.

Conflict-of-interest statement: The authors declare no conflict of interest.

Data sharing statement: No additional data are available.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Chang Xu, Kun Wang, Yu-Han Ding, Wen-Jing Li, Lei Ding, Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

Corresponding author: Lei Ding, MD, PhD, Associate Professor, Chief Doctor, Surgeon, Surgical Oncologist, Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, No. 10, Tieyi Road, Haidian District, Beijing 100038, China.

dinglei1005@126.com

Telephone: +86-10-63926296

Fax: +86-10-63926296

Abstract

BACKGROUND

Claudin-7, one of the important components of cellular tight junctions, is currently considered to be expressed abnormally in colorectal inflammation and colorectal cancer. However, there is currently no effective animal model to study its specific mechanism. Therefore, we constructed three lines of *Claudin-7* knockout mice using the Cre/LoxP system.

AIM

To determine the function of the tumor suppressor gene *Claudin-7* by generating three lines of *Claudin-7* gene knockout mice.

METHODS

We crossed *Claudin-7*-floxed mice with CMV-Cre, vil1-Cre, and villin-CreERT2 transgenic mice, and the offspring were self-crossed to obtain conventional *Claudin-7* knockout mice, conditional (intestinal specific) *Claudin-7* knockout mice, and inducible conditional *Claudin-7* knockout mice. Intraperitoneal injection of tamoxifen into the inducible conditional *Claudin-7* knockout mice can induce the knockout of *Claudin-7*. PCR and agarose gel electrophoresis were used to identify mouse genotypes, and Western blot was used to confirm the knockout of *Claudin-7*. The mental state, body length, and survival time of these mice were observed. The dying mice were sacrificed, and hematoxylin-eosin (HE) staining and immunohistochemical staining were performed to observe changes in intestinal structure and proliferation markers.

RESULTS

We generated *Claudin-7*-floxed mice and three lines of *Claudin-7* gene knockout mice using the Cre/LoxP system successfully. Conventional and intestinal specific *Claudin-7* knockout mice were stunted and died during the perinatal period, and intestinal HE staining in these mice revealed mucosal gland structure

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Received: October 24, 2018

Peer-review started: October 25, 2018

First decision: November 29, 2018

Revised: January 10, 2019

Accepted: January 18, 2019

Article in press: January 18, 2019

Published online: February 7, 2019

disappearance and connective tissue hyperplasia with extensive inflammatory cell infiltration. The inducible conditional *Claudin-7* knockout mice had a normal phenotype at birth, but after the induction with tamoxifen, they exhibited a dying state. Intestinal HE staining showed significant inflammatory cell infiltration, and atypical hyperplasia and adenoma were also observed. Intestinal immunohistochemistry analysis showed abnormal expression and distribution of Ki67, and the normal intestinal proliferation balance was disrupted. The intestinal crypt size in inducible conditional *Claudin-7* knockout mice was increased compared with control mice (small intestine: 54.1 ± 2.96 vs 38.4 ± 1.63 ; large intestine: 44.7 ± 1.93 vs 27.4 ± 0.60 ; $P < 0.001$).

CONCLUSION

The knockout of *Claudin-7* *in vivo* causes extensive inflammation, atypical hyperplasia, and adenoma in intestinal tissue as well as animal death in mice. *Claudin-7* may act as a tumor suppressor gene in the development of colorectal cancer.

Key words: Claudin-7; Gene knockout; Inflammation; Adenomas; Colorectal carcinoma

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The intestinal tract of conventional and intestinal specific *Claudin-7* knockout mice was characterized by extensive and severe inflammation. The development of inducible conditional knockout mice can control the knockout of *Claudin-7* in a temporal and compartment specific manner and prolong the survival time of mice, which exhibited atypical hyperplasia and adenoma in the intestine. This study revealed the inhibitory role that Claudin-7 plays in colorectal inflammation and colorectal cancer.

Citation: Xu C, Wang K, Ding YH, Li WJ, Ding L. *Claudin-7* gene knockout causes destruction of intestinal structure and animal death in mice. *World J Gastroenterol* 2019; 25(5): 584-599

URL: <https://www.wjgnet.com/1007-9327/full/v25/i5/584.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v25.i5.584>

INTRODUCTION

Members of the Claudin family serve as important components of cellular tight junctions (TJs), and they mainly function to maintain cell polarity, regulate intercellular small molecule flux, and facilitate cell proliferation and differentiation^[1-3]. Claudin-7 (Cldn7), one of the 27 members of the Claudin family, is mainly distributed in the stomach, lung, intestine, bladder, and kidney. Cldn7 was originally found in an extracellular Cl⁻ barrier and Na⁺ channel and shown to affect extracellular permeability^[4]. However, recent studies have shown that Cldn7 is abnormally expressed in different cancer tissues, especially in colon cancer, suggesting that alterations in its expression may affect the normal structure and function of TJs and be related to the occurrence of intestinal tumors^[5-8]. Cldn7 is currently considered to play an inhibitory role in colorectal inflammation and colorectal cancer by most scholars^[9-11].

The most effective way to study inhibitors *in vivo* is to knock out the gene in an animal and observe its overall phenotype. In recent years, the Cre/LoxP recombinase system has been widely used in novel gene targeting^[12,13]. LoxP was inserted at both ends of the *Cldn7* sequence to obtain heterozygous floxed mice. After crossing with CMV-Cre and villi-Cre mice, the sequence between the two LoxP sites was excised and inherited by daughter cells. Shimizu was the first to report time-specific gene knockout animal models in which the time of gene knockout could be artificially controlled by injection with an inducer^[14]. Therefore, we constructed conventional *Cldn7* gene knockout (CKO) mice and conditional knockout (cKO) mice using the Cre/LoxP system. We also generated inducible conditional *Cldn7* knockout (ICKO) mice and induced Cre expression by injecting tamoxifen. Hematoxylin-eosin (HE) staining showed that the intestinal structures in the CKO and cKO mice were severely damaged, and numerous inflammatory cells infiltrated. By injecting tamoxifen into

the ICKO mice, we successfully established atypical hyperplasia and intestinal adenoma models. Immunohistochemistry analysis indicated that the expression and distribution of Ki67 in the intestinal tissues were dysregulated. The successful construction of mouse intestinal inflammation and intestinal adenoma models could provide a basis for further studying the role of Cldn7 in intestinal tumors.

MATERIALS AND METHODS

Experimental animal species and animal care and use statement

We inserted a LoxP site into the intronic sequence downstream of exon 4 of the *Cldn7* gene and inserted the FRT-neo-FRT-LoxP element into the upstream intronic sequence of exon 2 to obtain *Cldn7*-floxed mice. The CMV-Cre mice were purchased from the National Resource Center for Mutant Mice, the vill1-Cre mice were obtained from the China Pharmaceutical University (from the Jackson Laboratory, USA), and the villin-CreERT2 mice were donated by professor Sylvie Robine. All mice were housed according to specific pathogen-free grade animal feeding standards at an indoor temperature of 20-26 °C and a 12-h day/night cycle. The mice were fed a standard diet after sterilization and had free access to food and water. All animals were euthanized for tissue collection. All animal assay protocols were reviewed and approved by the Medical Ethics Committee of the Capital Medical University Affiliated Beijing Shijitan Hospital Institutional Review Board.

Construction of Cldn7-floxed mice

We constructed a targeting vector as shown in Figure 1A. After the final vector was sequenced for validation, it was transfected into embryonic stem (ES) cells by electroporation. From the 8th-10th day, ES cell clones were picked, and genomic DNA was extracted, amplified, digested with the *EcoRV* enzyme overnight, and slowly electrophoresed for 36 h. The target clones were screened by long range PCR and Southern blot.

Approximately 4-wk-old C57BL/6N female mice were selected and injected with pregnant mare serum gonadotropin and human chorionic gonadotropin to promote ovulation. Embryos were harvested on the 2nd day after cohousing the female mice with the male mice, and 12-15 ES cells were injected into each blastocyst after culturing overnight. After the injection, the blastocysts were cultured for 3 h in an incubator, and those with a normal morphology and intact transparent bands were selected for transplantation. After 8-10 wk of sexual maturation, female C57BL/6N mice were selected for uterine blastocyst transplantation. The mice born after successful transplantation were identified by PCR, and those with the *fln/wt* genotype were deemed to be chimeric mice. Chimeric mice were crossed with Flper mice and then backcrossed with wild-type C57BL/6N mice to obtain *Cldn7*-floxed mice (genotype: *fln/wt*), which were missing the entire *Neo* resistance gene.

Construction of three lines of knockout mice

Cldn7-floxed mice were crossed with CMV-Cre mice, vill1-Cre mice, and villin-CreERT2 mice to obtain *Cldn7* CKO mice, *Cldn7* cKO mice, and *Cldn7* ICKO mice, respectively. Next, 50 mg of tamoxifen was dissolved in 5 mL of sterilized sunflower oil and mixed for 30 min to obtain the tamoxifen dilution. Six- to eight-wk-old ICKO mice were intraperitoneally injected with 100 µL of the tamoxifen dilution every 5 d to induce the *Cldn7* knockout.

Western blot

Various *Cldn7* knockout mouse tissues were minced on ice and mixed with appropriate grinding beads and total protein extraction reagents containing different protease inhibitors; a tissue homogenizer was then used to extract total protein. Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were incubated with a diluted rabbit polyclonal anti-Cldn7 antibody (1:1000, ab27487, Abcam, United States) at 4 °C overnight and then with a donkey anti-rabbit IgG antibody (1:10000, ab175780, Abcam). After blotting, the signals were detected with a Western blot scanner. GAPDH was used as the internal reference.

HE staining

The intestinal tissues of *Cldn7* knockout mice and control mice were washed in PBS and then placed in 10% formalin/PBS at 4 °C. After dehydration and clearing, the tissues were immersed in wax and then cut into 5-8-micron-thick sections. The sections were then dewaxed and stained with HE.




Figure 1 Strategic design and final vector sequencing results. A: Schematic diagram of the *Cldn7* gene knockout targeting vector; B-D: The first and second regions in red show the sequencing results at LoxP and FRT 5', while the grey region shows the FRT 3' sequencing results; B-D indicate that the *Cldn7* targeting vector was correct. *Cldn7*: Claudin-7.

Immunohistochemical staining

All tissues were embedded in wax blocks and cut into paraffin sections. After dewaxing, hydration, and antigen retrieval, the tissue sections were incubated for 10 min in 3% H₂O₂ and washed with 0.01 mol/L PBS. The sections were then incubated with a diluted rabbit polyclonal anti-Cldn7 antibody (ab27487, 1:200, Abcam, United States) and a rabbit monoclonal anti-Ki67 antibody (ab16667, 1:1000, Abcam, United States), followed by incubation with the corresponding horseradish peroxidase-labelled secondary antibody. The proteins were then developed in 3,3'-diaminobenzidine for coloration and assessment.

Statistical analysis

Statistical analyses were performed using IBM SPSS version 17.0 and GraphPad Prism version 6.0. All data are expressed as the mean \pm SD. Differences between two groups were analysed by Student's *t*-test and considered significant at $P < 0.05$.

RESULTS

Cldn7-floxed mice are constructed successfully

We constructed the *Cldn7* gene knockout targeting vector as shown in Figure 1A, and sequenced the final vector using a unidirectional primer (LoxP-tF: GTACGAGTTTGGACCTGCCA) to detect whether the 34 bp LoxP site was inserted correctly (Figure 1B). The LoxP site is shown in yellow, and the 3'-untranslated region is shown in green. FRT sequencing from the 5' end was performed using a unidirectional primer (Cldn7-FRT-tF: CTGATCTGGGTGTCCCACGT), as the FRT site serves as a screening marker for *Neo*. By removing the *Neo* resistance gene, the FRT site was also removed. The second LoxP site is shown in green, the FRT site is shown in yellow, and *Neo* is shown in purple (Figure 1C). FRT 3' sequencing was then performed (FRT-tR: CGATGAAACCGTTCCAGGTA), and the presence of another FRT site is shown in pink font (Figure 1D). Therefore, the final gene targeting vector was correct.

The targeting vector was electroporated into B6/BLU ES cells for targeting, and some drug-resistant ES cell clones were obtained. Two methods were used to prevent false-positive results and detect target clones, long range PCR and Southern blot. First, we tested whether the 5' homologous arm was correct (Figure 2A). The 5496 bp product was a positive clone containing LoxP. The 3' end was also detected (Figure 2B), and the 5204 bp product was a positive clone. The Southern blot results are shown in Figure 2C. Genomic DNA extracted from the transfected ES cells was digested with *Spe* I restriction endonuclease. Gene fragments of 17.8 kb and 9.5 kb were obtained from the *Cldn7* 5' end of the wild-type and target clones, respectively, and gene fragments of 17.8 kb and 7 kb were obtained from the *Cldn7* 3' end. When using the *EcoRV* restriction enzyme (probe on *Neo*), an 11.7 kb gene fragment was obtained from the target clone. The Southern blot results showed that clones 8D, 8E, 4F, 11E, and 11F were the final positive clones.

The positive clone 8D was selected for blastocyst injection, and the newborn mice after blastocyst transfer were genotyped by PCR. The primer information is shown in Table 1. The mice numbered 50 and 77 were deemed chimeric mice with the genotype *fln/wt* (Figure 2D). The chimeric mice were crossed with Flper mice to remove the *Neo* resistance gene, and the resulting mice were mated with wild-type C57BL/6N mice to completely delete the *Neo* resistance gene, successfully yielding *Cldn7*-floxed mice.

Cldn7 CKO mice die in the perinatal period and have severe intestinal damage

Cldn7-floxed mice were crossed with CMV-Cre mice, and the offspring were then self-crossed. Genomic DNA was isolated from the tails for genotyping. The primer information is shown in Table 2. The mouse with the Null/Null CreW genotype was considered the *Cldn7* CKO mouse. We considered newborn mice from the same litter as an example. We first evaluated whether *Neo* was completely deleted. None of the samples showed an *fln* band at 515 bp, indicating that *Neo* had been deleted completely. Furthermore, none of the samples showed the Cre band at 481 bp, suggesting that the genotype of all samples was CreW. Next, the banding results showed that mice numbered 1, 5, 6, and 10 had a null band at 640 bp, suggesting the presence of Cre-mediated recombination. The final step was to identify whether the mice were homozygous, and mouse 6 was determined to be homozygous for the Null/Null genotype. Therefore, mouse 6 was deemed the *Cldn7* CKO mouse with the Null/Null CreW genotype (Figure 3A).

Cldn7 CKO mice were born similarly to heterozygous and wild-type mice. However, the lengths of the *Cldn7* CKO mice increased significantly slower than those




Figure 2 Long range PCR and Southern blot for detecting target clones. A: The 5' homologous arm band was first detected, and the product with a length of 5496 bp was a positive clone containing LoxP; B: The 3' end was then detected, and the product with a length of 5204 bp was a positive clone; C: Southern blot results showing that clones 8D, 8E, 4F, 11E, and 11F were the final targeted clones; D: After blastocyst transfer, newborn mice were genotyped by PCR. The mice numbered 50 and 77 were deemed chimeric mice with the genotype *fln/wt*.

of the control mice ($P < 0.05$).

Beginning on the third day, CKO mice were thin, lacked energy, showed signs of lethargy, exhibited decreased body temperature, and had reduced activities, all of which suggested a state of dying (Figure 3B).

The dying mice were sacrificed, and their lungs, stomachs, bladders, kidneys, small intestines, and large intestines were collected. Western blot analysis showed that Cldn7 was not expressed in any of the tissues analyzed in CKO mice, while the control mice expressed Cldn7 in all of these tissues (Figure 3C). Intestinal HE staining showed obvious atrophy, thinning or loss of intestinal mucosa, connective tissue hyperplasia with inflammatory cell infiltration, residual intestinal mucosal epithelial vacuolar degeneration, villus shortening, and lymphatic expansion. Intestinal HE staining of the control mice showed no obvious histopathological changes (Figure 3D). Therefore, Cldn7 CKO mice showed significantly slow growth and appeared to be dying on the third day. HE staining showed severe intestinal destruction, loss of intestinal mucosal structure, and infiltration of numerous inflammatory cells.

Cldn7 cKO mice have longer survival times

Table 1 PCR primers for chimeric mouse genotyping and corresponding band results

Sequence (5'-3')	Results
Cldn7 loxP-tF primer : GTACGAGTTTGACCT GCCA	Fln/Fln = 493 bp; Fln/wt = 493/375 bp; wt/wt = 375 bp
Cldn7-LoxP-tR primer : TGTGCAA GGATCTGGGTCTG	
Cldn7-FRT-tF primer : CTGATCTGGGTGTCACCGT	Fln/Fln = 507 bp; Fln/wt = 507/0 bp; wt/wt = 0bp
ZMK-2F4 primer: GCATCGCATTGTCTGAG TAGGTG	
Neo-5R primer : GGCTGG ACGTAAACTCCTC	Fln/Fln = 259 bp; Fln/wt = 259/0bp; wt/wt = 0 bp
Cldn7-FRT-tR primer: CGATGAAACC GTTCCAGGTA	

Cldn7-floxed mice were crossed with *vil1-Cre* mice, and the offspring were then self-crossed. Genomic DNA was isolated for genotyping analysis. The mouse with the *Cldn7^{fl/fl}*; villin-CreT (*fl/fl* CreT) genotype was deemed the *Cldn7* cKO mouse. None of the samples showed a fln band at 515 bp or a null band at 640 bp, indicating that *Neo* had been deleted completely and that no Cre recombination occurred. We next detected whether flper recombination occurred by the detection of an *fl* band at 756 bp. The results showed that No. 213 mouse had the *fl/wt* genotype, while all other mice had the *fl/fl* genotype. Finally, Cre was detected, and a band at 481 bp, which corresponded to CreT, was observed in mice numbered 213, 215, and 217, while all other mice displayed a band corresponding to CreW. Therefore, the mice numbered 215 and 217 were deemed *Cldn7* cKO mice (Figure 4A).

Cldn7 cKO mice were normal at birth compared to control mice. But *Cldn7* cKO mice were obviously thin, their body length increased slowly from the 5th day after birth, and their growth rate was significantly slower than that of control mice ($P < 0.05$). On the 9th day, *Cldn7* cKO mice appeared to be languid, with reduced or even inactive activities, leaving only a slight breath. The body temperature of the mouse was reduced and it was in a state of dying (Figure 4B).

The dying mice were sacrificed, and we found that the expression levels of *Cldn7* in the lung, stomach, bladder, and kidney tissues of cKO mice were normal, while *Cldn7* expression was absent in the small and large intestines. All control mouse tissues expressed *Cldn7* (Figure 4C). Intestinal HE staining showed obvious mucosal atrophy, mucosal gland structure disappearance, and connective tissue hyperplasia with extensive inflammatory cell infiltration. Inflammatory lesions were observed everywhere (Figure 4D), and mucosal epithelial vacuolar degeneration was observable after magnification. No obvious histopathological changes were observed in the mucosal glands, submucosa, or muscular layers of the intestines of *fl/fl* CreW mice. *Cldn7* cKO mice excluded the influence of other organs lacking *Cldn7* expression on mice and prolonged the survival time. However, because the cKO mice still showed intestinal inflammation, we generated *Cldn7* ICKO mice on this basis to try to obtain an adenoma model.

***Cldn7* ICKO mice display atypical hyperplasia and adenoma and dysregulated proliferation in the intestine**

Cldn7-floxed mice were crossed with villin-CreERT2 mice, and the offspring were then self-crossed. PCR and agarose gel electrophoresis results showed the mice numbered 135-137, 139-142, and 144 were *Cldn7* ICKO mice with the genotype of *Cldn7^{fl/fl}*; villin-CreERT2 (*fl/fl* CreERT2) (Figure 5A).

Cldn7 ICKO mice were normal at birth and developed smoothly, unlike *Cldn7^{fl/fl}*; villin-CreW (*fl/fl* CreW) mice (Figure 5B left). A tamoxifen solution (10 mg/mL, 100 μ L) was intraperitoneally injected into 6 to 8-wk-old ICKO mice every 5 d. Beginning at the 7th injection, the ICKO mice were lethargic and lack of activity, appeared thin, and exhibited a dying state, while the control mice showed no abnormalities (Figure 5B left). All ICKO mice died within 75 d (15 tamoxifen injections, Figure 5B right).

Both the dying mice and control mice were sacrificed. The expression levels of *Cldn7* in the lung, stomach, bladder, and kidney tissues of ICKO mice were normal, but *Cldn7* expression was absent in their small and large intestines. All control mouse tissues expressed *Cldn7* (Figure 5C). Intestinal HE staining showed obvious inflammatory manifestations (Figure 5D, E, G, and H), numerous infiltrated inflammatory cells, abnormal or absent intestinal villi and intestinal gland structure, mucosal epithelial cell shedding, and disordered residual villus mucosal epithelial cells that lacked polarity. Atypical hyperplasia (Figure 5J and M) and intestinal adenoma (Figure 5K and N) were also observed. The intestinal structure was normal and intact in the control mice (Figure 5F, I, L, and O), with no obvious pathological changes observed.

Table 2 PCR primers for gene knockout mouse genotyping and corresponding explanations

Primer sequence (5'-3')	Results	Description
Cldn7-FRTtF2: CCTGGGATCTGATCTGGGTG Cldn7-FRTtR2: GGCAGGTAGCCTTAGGATGG	wt = 600 bp, fln = none; fl = 756 bp, Null = none	Check if flper is reorganized
ZMK2F4: GCATCGCATTGTCTGAGTAGGTG Cldn7-FRTtF2: CCTGGGATCTGATCTGGGTG	wt = none, fln = 515 bp; fl = none, Null = none	Check if <i>Neo</i> is deleted completely
Cldn7-loxPtF2: CTTGGGAGACATCAGGTCCG Cldn7-loxPtR2: GAGGCAATAGGCCCAAGGAG	wt = 512 bp, fln = 630 bp; fl = 630 bp, Null = none	Homozygous identification
Cldn7-FRTtF2: CCTGGGATCTGATCTGGGTG Cldn7-loxPtR2: GAGGCAATAGGCCCAAGGAG	wt = none, fln = none; fl = none, Null = 640 bp	Check if Cre mediated recombination occurs
Cre-up: GCCTGCATTACCGTTCGATGC Cre-low: CAGGGTGTATAAGCAATCCC	T: 481 bp; W: none	Detect Cre

Immunohistochemistry analysis was also used to detect the expression of intestinal Cldn7 and the nuclear proliferation marker Ki67 in ICKO and control mice, revealing that Cldn7 was strongly expressed in the intestinal epithelial junction of control mice, but was significantly weakened in the intestines of ICKO mice (Figure 6A-D). In addition, the expression of Ki67 was also altered. In control mice, Ki67 was mainly distributed in portions of the crypt, while Ki67-positive cells occupied the entire intestinal crypt in ICKO mice (Figure 6E-H). The intestinal crypt size in ICKO mice was increased compared with that in control mice (Figure 6I and J). Furthermore, Ki67 was mostly expressed in the crypt area in control mice, while Ki67 in the intestinal tract of the ICKO mice was no longer confined to the crypt area. Cells expressing Ki67 were observed throughout the entire intestinal villi, and this manifestation was more pronounced in the large intestine.

DISCUSSION

Abnormal expression of Cldn7 can lead to the destruction of TJ structure and function as well as cell proliferation and migration abnormalities^[15], which are closely related to the occurrence and development of malignant tumors, such as lung cancer, ovarian cancer, and gastric cancer^[16-18]. However, the specific mechanisms underlying these phenomena remain elucidated.

Cldn7 is widely considered to be a tumor-suppressor gene^[19-21], and one of the best methods for researching tumor-suppressor genes is to knock out the gene *in vivo* and then observe the phenotype of the entire animal^[22]. Tamura *et al.*^[23] generated *Cldn15*^{-/-} mice using the conventional gene targeting strategy. *Cldn15* is similar to Cldn7 and strongly expressed in the duodenum, jejunum, ileum, and colon, while other Claudin family proteins, such as Cldn6, 9, 10, 11, and 14, are not expressed in the intestine^[20]. *Cldn15*-deficient mice formed mega-intestines, in which the upper small intestine was two times larger than the normal intestine. Moreover, because *Cldn15* deletion is not lethal, researchers can observe intestinal development at different time points, such as at 1 wk, 4 wk, and 10 wk after birth^[22]. Similarly, we constructed *Cldn7* CKO mice using the same strategy, and this mouse model showed severe intestinal defects that included mucosal ulcerations, epithelial cell sloughing, and inflammation. However, *Cldn7* CKO mice died beginning on the third day, which was not conducive to long-term observation or subsequent experiments. Additionally, the effects of *Cldn7* deletion in other organs on survival time and morphological changes could not be excluded. Therefore, prolonging the survival time of *Cldn7* knockout mice is necessary for further studying the function of Cldn7.

The Cre/LoxP technology makes it possible to knock out a gene in a site- or time-specific manner^[22]. Cre recombinase can be expressed in specific cell types, and the crossing between floxed mice and Cre mice can then be used to remove the sequence between two LoxP sites in specific tissues. When Cre recombinase is fused to a ligand-binding domain of a mutant human estrogen receptor (ER), it becomes a tamoxifen-dependent Cre recombinase (Cre-ERT)^[24]. Time-specific gene knockout can be achieved by injecting tamoxifen into transgenic mice at different growth stages. Using this method, we constructed intestinal specific *Cldn7* cKO mice. A Western blot assay confirmed that only intestinal *Cldn7* was ablated. While *Cldn7* cKO mice had a normal phenotype after birth, by the fifth day, the mice grew slowly and lacked energy. On the 9th day, the dying mice were sacrificed; their intestinal tracts showed severe




Figure 3 Phenotypic and intestinal pathological changes in *Cldn7* CKO mice. A: Genotype analysis showed that No. 6 mouse was a *Cldn7* CKO mouse with the genotype *Null/Null* CreW. Marker: 8000/5000/3000/2000/1000/750/500/250/100 bp; B: *Cldn7* CKO mice were similar to control mice at birth but grew slower than control mice ($P < 0.05$); from the third day, CKO mice appeared in a dying state; C: CKO mice expressed no *Cldn7* in any tissues, while all tissues of control mice expressed *Cldn7*; D: Intestinal HE staining in *Cldn7* CKO mice showed obvious atrophy of intestinal mucosa with inflammatory cell infiltration (as indicated by the

arrow), villus shortening, and lymphatic expansion (as indicated by the arrowhead); the control mice showed no obvious histopathological changes (as indicated by the arrow). Cldn7: Claudin-7; CKO: Conventional knockout.

inflammation, and their mucosal or glands appeared abnormal. Tanaka *et al* also constructed intestinal specific *Cldn7* cKO mice^[25], which had a longer survival period of 28 d due to the use of a different Cre enzyme mouse model. They found that intestinal *Cldn7* knockout changed only the paracellular flux of small molecule solutes and did not completely destroy the TJ structure. However, both knockout mice are intestinal inflammation models not yet showing adenomas or tumors. We further constructed *Cldn7* ICKO mice and controlled their survival time and intestinal morphological changes by changing the dose and frequency of tamoxifen. When the mice received 1 mg of tamoxifen every day, they began dying after the 5th injection, and severe inflammation was observed in the intestine (data not shown). When the mice received 1 mg of tamoxifen every 5 d, they began to show signs of dying after the 7th injection, and all mice died within 15 tamoxifen injections. Approximately 71.4% of the mice developed adenomas in different regions, including the duodenum, jejunum, ileum, and colon.

Immunohistochemical staining showed that compared with that in control mice, the intestinal crypt size in ICKO mice was increased, and cells positively expressing Ki67 covered the entire crypt. Ki67 expression was no longer limited to the crypt but rather to the crypt-villus axis. These phenomena suggested that the loss of *Cldn7* led to both expansion of the intestinal crypt and proliferation of cells at the crypt, and the normal proliferation-differentiation balance of intestinal cells along the crypt-villus axis was disrupted.

In the intestine, proliferating epithelial cells are specifically confined to the crypts^[26]. Recent studies have shown that the crypt microenvironment is important for the generation and maintenance of proliferating cells^[27]. Because TJs play a critical role in maintaining intestinal homeostasis, they may be important for formation of the niche, the microenvironment of the crypt for stem and transit-amplifying cells^[24]. Therefore, the construction of *Cldn7* ICKO mice is of great significance for studying the relationship among intestinal barrier destruction, dysregulation of intestinal stem cell proliferation and differentiation along the crypt-villus axis, changes in the intestinal crypt microenvironment, and intestinal tumor formation.

In conclusion, we report the novel findings that *Cldn7* knockout caused extensive inflammation, atypical hyperplasia, and adenoma in intestinal tissue as well as animal death in three lines of knockout mice. Therefore, *Cldn7* may act as a tumor suppressor gene in the development of colorectal cancer, and the specific mechanism of *Cldn7* can be elucidated by performing further research on the ICKO mouse model.




Figure 4 Phenotypic and intestinal pathological changes in *Cldn7* cKO mice. A: Genotype analysis showed the mice numbered 215 and 217 were intestinal specific *Cldn7* cKO mice with the genotype *Cldn7*^{fl/fl}; villin-CreT; B: *Cldn7* cKO mice were normal at birth, but their body lengths increased more slowly from the fifth day after birth than those of control mice ($P < 0.05$); on the 9th day, cKO mice were in poor spirits and died thereafter; C: *Cldn7* expression was normal in the lung, stomach, bladder, and kidney tissues of cKO mice but absent in the small and large intestines; all tissues of the control mice expressed *Cldn7*; D: Intestinal hematoxylin-eosin staining in *Cldn7* cKO mice showed connective tissue hyperplasia with extensive inflammatory cell infiltration in the submucosa (as indicated by the arrow); mucosal epithelial vacuolar degeneration can be observed after magnification (as indicated by the arrowhead); there were no obvious histopathological changes in *fl/fl* CreW mice. *Cldn7*: Claudin-7; cKO: Conditional knockout.




Figure 5 Phenotypic and intestinal pathological changes in *Cldn7* ICKO mice. A: Genotype analysis showed that mice numbered 135-137, 139-142, and 144 were *Cldn7* ICKO mice with the genotype *Cldn7*^{fl/fl}; villin-CreERT2; B: *Cldn7* cKO mice were normal at birth and developed smoothly, but beginning at the 7th injection, ICKO mice were in poor health and appeared to be dying; all ICKO mice died within 15 tamoxifen injections; C: *Cldn7* was expressed at normal levels in the lung, stomach, bladder, and kidney tissues of ICKO mice but absent in the small and large intestines; all tissues of the control mice expressed *Cldn7*; D-O: Intestinal hematoxylin-eosin staining in ICKO mice showed obvious inflammatory manifestations; atypical hyperplasia and intestinal adenoma were also observed; the intestinal structure of the control mice was normal. Tamoxifen was dissolved in sunflower oil at a concentration of 10 mg/mL, and each mouse was intraperitoneally injected at 1 mg every 5 days. *Cldn7*: Claudin-7; cKO: Conditional knockout; ICKO: Inducible conditional knockout.




Figure 6 Increased intestinal proliferation in *Cldn7* ICKO mice. A-D: Immunohistochemistry staining showed that *Cldn7* was strongly expressed in the intestinal epithelial junctions of control mice but significantly weakened in ICKO mice; E-H: In control mice, *Ki67* was mainly distributed in parts of the crypt, while *Ki67*-positive

cells occupied the entire intestinal crypt and could be observed throughout the intestinal villi in ICKO mice; I-J: The size of the intestinal crypt in ICKO mice was increased compared with that in control mice ($P < 0.001$). Cldn7: Claudin-7; ICKO: Inducible conditional knockout.

ARTICLE HIGHLIGHTS

Research background

Claudin-7, one of the important components of cellular tight junctions, is currently considered to be expressed abnormally in colorectal inflammation and colorectal cancer. However, there is currently no effective animal model to study its specific mechanisms. Therefore, we constructed three lines of *Claudin-7* knockout mice using the Cre/LoxP system to provide a basis for further studying the role of Claudin-7 in intestinal tumors.

Research motivation

Claudin-7 is currently considered to play an inhibitory role in colorectal inflammation and colorectal cancer. The most effective way to study inhibitors *in vivo* is to knock out the gene in an animal and observe its overall phenotype. Therefore, we constructed conventional *Claudin-7* gene knockout (CKO) mice and conditional *Claudin-7* gene knockout (cKO) mice using Cre/LoxP system, and we also generated inducible conditional *Claudin-7* gene knockout (ICKO) mice and induced Cre expression by injecting tamoxifen. The successful construction of these mouse lines as intestinal inflammation and intestinal adenoma models could provide a basis for further studying the role of Claudin-7 in intestinal tumors.

Research objectives

The main objective was to construct three lines of *Claudin-7* gene knockout mice to achieve space- and time-specific knockout of *Claudin-7* and prolong the survival time of mice. Due to the prolonged growth time of mice, the organs matured when *Claudin-7* was knocked out. So this animal model can provide a basis for further study of Claudin-7.

Research methods

We constructed three lines of *Claudin-7* knockout mice using the Cre/LoxP system. First, chimeric mice were constructed by transfecting the target vector into embryonic stem cells, screening the hybrid clones and injecting them into the female mouse blastocysts, and transplanting the blastocysts into the female mouse uterus. Chimeric mice were then purified to obtain *Claudin-7*-floxed mice. Second, *Claudin-7*-floxed mice were crossed with CMV-Cre mice, villin-Cre mice, and villin-CreERT2 mice to obtain *Claudin-7* CKO mice, *Claudin-7* cKO mice, and *Claudin-7* ICKO mice, respectively. ICKO mice were induced by intraperitoneal injection of tamoxifen to knockout *Claudin-7* in intestinal tissue. Finally, Western blot was used to verify the knockout efficiency of Claudin-7. Hematoxylin-eosin (HE) staining was used to confirm the structural changes and pathological changes of the intestinal tract in *Claudin-7* knockout mice. Immunohistochemical staining was used to observe the proliferation markers. The construction of cKO mice prolonged the lifespan of CKO mice, and the ICKO mouse was the first animal model to specifically knock out *Claudin-7* in a spatial and temporal manner.

Research results

We generated *Claudin-7*-floxed mice and three lines of *Claudin-7* gene knockout mice successfully. *Claudin-7* CKO mice and *Claudin-7* cKO mice were stunted and died during the perinatal period, and intestinal HE staining revealed mucosal gland structure disappearance and connective tissue hyperplasia with extensive inflammatory cell infiltration. *Claudin-7* ICKO mice had a normal phenotype at birth, but after the induction with tamoxifen, the mice exhibited a dying state. Intestinal HE staining showed significant inflammatory cell infiltration, and atypical hyperplasia and adenoma were also observed. Intestinal immunohistochemistry analysis showed abnormal expression and distribution of Ki67, and the normal intestinal proliferation balance was disrupted.

Research conclusions

This study innovatively constructed three lines of *Claudin-7* gene knockout mice, which clarified that Claudin-7 plays an inhibitory role in colon inflammation and colon adenoma, and initially found that Claudin-7 may promote the development of colon adenomas by affecting proliferation. This study successfully simulated intestinal inflammation and intestinal adenoma, and proposed new animal models. This study clarified the role of Claudin-7 in colonic inflammation and tumors, laying the groundwork for finding early clinical diagnosis and potential therapeutic targets.

Research perspectives

This article describes the construction of *Claudin-7*-floxed mice and the process of crossing with three Cre mice. Based on this experience, we can construct ICKO mice in which *Claudin-7* is ablated in the kidney, skin, and some other organs, and then observe changes in mice before and after *Claudin-7* deletion. In the next step of the study, the dose of tamoxifen should be clarified,

and the tumor should be induced in the intestinal tract of ICKO mice. The direction of the future research is to clarify the specific mechanism of Claudin-7 in inflammatory bowel disease and intestinal tumorigenesis, invasion, and metastasis; and to explore the relationship between Claudin-7 and stem cells as well as its role in intestinal development.

ACKNOWLEDGEMENTS

We thank the National Resource Center for Mutant Mice for their assistance and technical support.

REFERENCES

- 1 **Van Itallie CM**, Anderson JM. Claudins and epithelial paracellular transport. *Annu Rev Physiol* 2006; **68**: 403-429 [PMID: 16460278 DOI: 10.1146/annurev.physiol.68.040104.131404]
- 2 **Ding L**, Lu Z, Lu Q, Chen YH. The claudin family of proteins in human malignancy: A clinical perspective. *Cancer Manag Res* 2013; **5**: 367-375 [PMID: 24232410 DOI: 10.2147/CMAR.S38294]
- 3 **Farkas AE**, Capaldo CT, Nusrat A. Regulation of epithelial proliferation by tight junction proteins. *Ann N Y Acad Sci* 2012; **1258**: 115-124 [PMID: 22731724 DOI: 10.1111/j.1749-6632.2012.06556.x]
- 4 **Alexandre MD**, Lu Q, Chen YH. Overexpression of claudin-7 decreases the paracellular Cl⁻ conductance and increases the paracellular Na⁺ conductance in LLC-PK1 cells. *J Cell Sci* 2005; **118**: 2683-2693 [PMID: 15928046 DOI: 10.1242/jcs.02406]
- 5 **Darido C**, Buchert M, Pannequin J, Bastide P, Zalzal H, Mantamadiotis T, Bourgaux JF, Garambois V, Jay P, Blache P, Joubert D, Hollande F. Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells. *Cancer Res* 2008; **68**: 4258-4268 [PMID: 18519685 DOI: 10.1158/0008-5472.CAN-07-5805]
- 6 **Akizuki R**, Shimobaba S, Matsunaga T, Endo S, Ikari A. Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma. *Biochim Biophys Acta Mol Cell Res* 2017; **1864**: 293-302 [PMID: 27884700 DOI: 10.1016/j.bbamer.2016.11.018]
- 7 **Tsujiwaki M**, Murata M, Takasawa A, Hiratsuka Y, Fukuda R, Sugimoto K, Ono Y, Nojima M, Tanaka S, Hirata K, Kojima T, Sawada N. Aberrant expression of claudin-4 and -7 in hepatocytes in the cirrhotic human liver. *Med Mol Morphol* 2015; **48**: 33-43 [PMID: 24737165 DOI: 10.1007/s00795-014-0074-z]
- 8 **Garcia-Hernandez V**, Quiros M, Nusrat A. Intestinal epithelial claudins: Expression and regulation in homeostasis and inflammation. *Ann N Y Acad Sci* 2017; **1397**: 66-79 [PMID: 28493289 DOI: 10.1111/nyas.13360]
- 9 **Schölch S**, Garcia SA, Iwata N, Niemietz T, Betzler AM, Nanduri LK, Bork U, Kahlert C, Thepkaysone ML, Swiersy A, Büchler MW, Reissfelder C, Weitz J, Rahbari NN. Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer. *Oncotarget* 2016; **7**: 27232-27242 [PMID: 27029058 DOI: 10.18632/oncotarget.8373]
- 10 **Oshima T**, Miwa H, Joh T. Changes in the expression of claudins in active ulcerative colitis. *J Gastroenterol Hepatol* 2008; **23** Suppl 2: S146-S150 [PMID: 19120888 DOI: 10.1111/j.1440-1746.2008.05405.x]
- 11 **Ding L**, Wang L, Sui L, Zhao H, Xu X, Li T, Wang X, Li W, Zhou P, Kong L. Claudin-7 indirectly regulates the integrin/FAK signaling pathway in human colon cancer tissue. *J Hum Genet* 2016; **61**: 711-720 [PMID: 27121327 DOI: 10.1038/jhg.2016.35]
- 12 **Trinh KR**, Morrison SL. Site-specific and directional gene replacement mediated by Cre recombinase. *J Immunol Methods* 2000; **244**: 185-193 [PMID: 11033031 DOI: 10.1016/S0022-1759(00)00250-7]
- 13 **Le Y**, Sauer B. Conditional gene knockout using Cre recombinase. *Mol Biotechnol* 2001; **17**: 269-275 [PMID: 11434315 DOI: 10.1385/MB:17:3:269]
- 14 **Shimizu E**, Tang YP, Rampon C, Tsien JZ. NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. *Science* 2000; **290**: 1170-1174 [PMID: 11073458 DOI: 10.1126/science.290.5494.1170]
- 15 **Singh AB**, Dhawan P. Claudins and cancer: Fall of the soldiers entrusted to protect the gate and keep the barrier intact. *Semin Cell Dev Biol* 2015; **42**: 58-65 [PMID: 26025580 DOI: 10.1016/j.semedb.2015.05.001]
- 16 **Lu Z**, Ding L, Hong H, Hoggard J, Lu Q, Chen YH. Claudin-7 inhibits human lung cancer cell migration and invasion through ERK/MAPK signaling pathway. *Exp Cell Res* 2011; **317**: 1935-1946 [PMID: 21641901 DOI: 10.1016/j.yexcr.2011.05.019]
- 17 **Dahiya N**, Becker KG, Wood WH, Zhang Y, Morin PJ. Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion. *PLoS One* 2011; **6**: e22119 [PMID: 21789222 DOI: 10.1371/journal.pone.0022119]
- 18 **Johnson AH**, Frierson HF, Zaika A, Powell SM, Roche J, Crowe S, Moskaluk CA, El-Rifai W. Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. *Am J Pathol* 2005; **167**: 577-584 [PMID: 16049341 DOI: 10.1016/S0002-9440(10)62999-9]
- 19 **Usami Y**, Chiba H, Nakayama F, Ueda J, Matsuda Y, Sawada N, Komori T, Ito A, Yokozaki H. Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. *Hum Pathol* 2006; **37**: 569-577 [PMID: 16647955 DOI: 10.1016/j.humpath.2005.12.018]
- 20 **Bornholdt J**, Friis S, Godiksen S, Poulsen SS, Santoni-Rugiu E, Bisgaard HC, Lothe IM, Ikdahl T, Tveit KM, Johnson E, Kure EH, Vogel LK. The level of claudin-7 is reduced as an early event in colorectal carcinogenesis. *BMC Cancer* 2011; **11**: 65 [PMID: 21310043 DOI: 10.1186/1471-2407-11-65]
- 21 **Lu Z**, Kim DH, Fan J, Lu Q, Verbanac K, Ding L, Renegar R, Chen YH. A non-tight junction function of claudin-7-Interaction with integrin signaling in suppressing lung cancer cell proliferation and detachment. *Mol Cancer* 2015; **14**: 120 [PMID: 26081244 DOI: 10.1186/s12943-015-0387-0]
- 22 **Metzger D**, Chambon P. Site- and time-specific gene targeting in the mouse. *Methods* 2001; **24**: 71-80 [PMID: 11327805 DOI: 10.1006/meth.2001.1159]
- 23 **Tamura A**, Kitano Y, Hata M, Katsuno T, Moriwaki K, Sasaki H, Hayashi H, Suzuki Y, Noda T, Furuse M, Tsukita S, Tsukita S. Megaintestine in claudin-15-deficient mice. *Gastroenterology* 2008; **134**: 523-534

- [PMID: 18242218 DOI: 10.1053/j.gastro.2007.11.040]
- 24 **el Marjou F**, Janssen KP, Chang BH, Li M, Hindie V, Chan L, Louvard D, Chambon P, Metzger D, Robine S. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. *Genesis* 2004; **39**: 186-193 [PMID: 15282745 DOI: 10.1002/gene.20042]
 - 25 **Tanaka H**, Takechi M, Kiyonari H, Shioi G, Tamura A, Tsukita S. Intestinal deletion of Claudin-7 enhances paracellular organic solute flux and initiates colonic inflammation in mice. *Gut* 2015; **64**: 1529-1538 [PMID: 25691495 DOI: 10.1136/gutjnl-2014-308419]
 - 26 **Cheng H**, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell types. *Am J Anat* 1974; **141**: 537-561 [PMID: 4440635 DOI: 10.1002/aja.1001410407]
 - 27 **Matsuda M**, Kubo A, Furuse M, Tsukita S. A peculiar internalization of claudins, tight junction-specific adhesion molecules, during the intercellular movement of epithelial cells. *J Cell Sci* 2004; **117**: 1247-1257 [PMID: 14996944 DOI: 10.1242/jcs.00972]

P- Reviewer: McMillin MA, Subramanian VS

S- Editor: Yan JP **L- Editor:** Wang TQ **E- Editor:** Huang Y





Published By Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

